An attempt was made to assess the quality and compare the physicochemical equivalence of six brands of ciprofloxacin tablets marketed in Tigray, Ethiopia. Six brands of ciprofloxacin tablets were used in the study. Identity, weight uniformity test, disintegration test, dissolution test and assay for the content of active ingredients were performed using the methods described in the British Pharmacopoeia. All the samples passed the identity, disintegration, and dissolution tests but Ciflox failed to release 80% of the drug content within 30 minutes as stipulated in the pharmacopoeia. This product therefore does not comply with the BP 2004 dissolution tolerance limits. All of the brands examined pass the assay for content of active ingredient. This work revealed that the six brands included in the study complied with the physicochemical quality parameters except Ciflox which failed to meet the pharmacopoeial specification for dissolution test. Nevertheless the six brands showed that there is significant difference in the drug release in vitro (p<0.05). To justify the specification limits of the in vitro dissolution test, an attempt should be made to establish a meaningful correlation between in vitro release characteristics and in vivo bioavailability parameters.
INTRODUCTION
The safety and efficacy of drug products can be guaranteed when their quality is reliable and reproducible from batch to batch. To ensure the requisite quality, drug manufacturers are required to test their products during and after manufacturing and at various intervals during the shelf life of the product (Chow, 1997) . The quality of medicines is an integral part of access in light of ensuring that the pharmaceutical products are fit for their intended use, comply with the requirement of the marketing authorization and do not expose consumers to risks. To attain this objective there must be a system of quality assurance, which incorporates aspects including product development, manufacture, distribution, and storage. Many developing countries do not have an effective means of monitoring the quality of generic drug products in the market. This results in widespread distribution of substandard and/or counterfeit drug products. It was in view of this fact that the World Health Organization (WHO) issued guidelines for global standard and requirements for the registration, assessment, marketing, authorization, and quality control of generic pharmaceutical products (WHO, 1996; WHO, 2005) .
The combination of market forces, the low per capita spending on pharmaceuticals by most of the population and the lack of adequate resources for controlling and monitoring the quality of drugs on the market creates an environment favorable for introducing low quality drugs in developing countries. Until very recently, the focus of developing country health advocates has been getting drugs into the supply chain at affordable prices. The quality of these drugs and the threat of counterfeit pharmaceuticals have been largely ignored. However, there is mounting evidence that counterfeit pharmaceuticals pose a serious threat to public health, especially in developing countries (Pecoul et al., 1999; WHO, 2005) .
According to the United States Food and Drug Administration (FDA), bioavailability and bioequivalence of drug products, and drug product selection have emerged as critical issues in pharmacy and medicine during the last three decades. Concern about lowering health care costs has resulted in a tremendous increase in the use of generic drug products; currently about one half of all prescriptions written are for drugs that can be substituted with a generic product (Miller, 1990) . In 1975, approximately 9% of all prescription drugs dispensed were generic versions. This percentage rose to 20% in 1984, and 40% in 1991. Indeed substitution of generic drugs for brand name products is highly controversial and is often met with suspicion by health care providers and patients (Covington, 1992; Meredith, 2003) . The FDA has mandated that all generic drugs meet the same standards as the brand name drugs in strength, safety, purity and performance. However, there are substandard and/or counterfeit generic drugs that don't satisfy the pharmacopoeial standards set for them.
In several developing countries, drug quality is a source of concern. There is a general feeling that there is a high incidence of drug preparations, which are not of acceptable quality (Ten Ham, 1992) . Counterfeit pharmaceuticals comprise a significant and growing problem. Pharmaceutical counterfeiting is a pervasive problem, impacting nations of every size and income level and drugs of every description (Alubo, 1994; Graciela, 2001 ). There are many reports of the availability of counterfeit medicines, not only in developing countries but also in Europe and USA (Shakoor et al., 1997) .
Reports indicate that there are substandard drugs circulating in the market in different developing countries. Marketing of such drugs has been widely reported in Africa, Asia, and Latin America.
In 2003, WHO reported that fake drugs reported between 1999 and 2002 include analgesics and antipyretics (6%), antimalarials (7%), anti-asthma and anti-allergy (8%), antibiotics (28%), hormones and steroids (18%) and other therapeutic categories (33%). Thus, the aforementioned problems have resulted in a weak therapeutic efficiency, selection of resistance strains and poor quality of numerous drugs (Menkes, 1997; Newton et al., 2001; Taylor et al., 2001 ).
Lack of competent regulatory authorities and poor quality control practices in some countries, have allowed the availability of poor quality drugs. These could be the widespread counterfeiting of medicines, decomposition of the active ingredient in drug dosage form due to high temperature and humidity of the storage condition, and inadequate quality assurance systems during the manufacture of pharmaceutical products (Risha et al., 2003; Kaymba et al., 2004; Hebron et al., 2005) .
Preliminary physicochemical assessment of drug products has a paramount importance in ensuring the quality of drug products. Generic drug products must satisfy the same standards of quality, efficacy and safety as those applicable to the innovator products. In vitro dissolution testing can be a valuable predictor of the in vivo bioavailability and bioequivalence of oral solid dosage forms (Itiola and Pilpel, 1996) . Thus, the present study was carried out to evaluate the physicochemical quality and equivalence of six brands of ciprofloxacin tablets purchased from retail pharmacy outlets in Mekelle using in vitro methods. The preliminary study was aimed at obtaining baseline data towards the establishment of bioequivalence of the tablets thereby rendering information for regulatory bodies as well as manufacturers to ensure the quality of these essential drug products through monitoring by post-marketing surveillance. Table 1 shows the detailed information on ciprofloxacin tablet formulations included in the study. The drugs were selected on the basis of being included in the Ethiopian national drug list obtained from the Ethiopian Drug Administration and Control Authority (DACA). Ciprofloxacin tablets were obtained from the retail outlets mainly from private pharmacies and drug stores in Mekelle, Tigray. The drug samples were anonymously purchased in their original package as supplied by the manufacturers and protected from direct sunlight. 
MATERIALS AND METHODS

Materials
Instruments and equipment
A high performance liquid chromatography (HPLC), a Pharma test dissolution tester, a UV/VIS spectrophotometer, an Ultrasonicator, an Electronic micro balance, and a high performance thin layer chromatography (HPTLC) aluminum sheets were used for the study.
Chemicals and reagents
The following chemicals and reagents were used in the study: Acetonitrile and ammonia HPLC grade, BDH (UK), dichloromethane, orthophosphoric acid, Methanol and Triethylamine, HPLC grade, were obtained from Sigma-Aldrich (Germany). Water, double distilled and deionized inhouse. The Ciprofloxacin HCl working standard, Lot Number XLM0725369 with purity or potency of 99.87% was obtained from Aurobindo pharmaceutical industries (India).
Methods
Six brands of ciprofloxacin 500 mg tablets were used in the study. Identity, weight uniformity, dissolution test and assay for the content of active ingredients were done as described in the British Pharmacopoeia (BP, 2004) . All the assays were carried out in triplicate except the dissolution tests which were done six times as indicated in BP. Dissolution profiles were constructed for each drug product.
Identification test
The identity of the drug was confirmed by high performance thin layer chromatography (HPTLC) with silica gel 60F 254 pre-coated (10x20) cm obtained from Merck (UK). The mobile phase was consisted of a mixture of methanol, dichloromethane, ammonia and acetonitrile 
Weight uniformity test
The test for uniformity of weight for each brand of ciprofloxacin tablets was carried out as described in BP 2004. The weights of twenty tablets were determined individually using an electronic micro balance; model AAA 250L, Adams Co. (UK). The mean tablet weight and standard deviation were calculated.
Disintegration time (DT) test
Disintegration time test for the tablets was carried out according to the specification given in BP 2004. A 900 ml beaker was filled with 37 ± 0.5 o C water. Six tablets were placed into the basketrack assembly and connected to the disintegration apparatus. The apparatus and the timer were started simultaneously and the time required for each tablet to disintegrate was recorded and the average time calculated.
Dissolution
Dissolution test was done according to BP 2004 specifications using dissolution apparatus type II (Paddle apparatus) obtained from Pharma test (Germany). Vessels consisting of 900 ml of water as the dissolution medium were employed. The vessels were added to a circulating water bath maintained at 37 ± 0.5 o C and allowed to equilibrate. Once the desired temperature was attained, the tablets were added to the center bottom of the vessel and the paddle was rotated at 50 rpm. 10 ml samples of the dissolution medium were withdrawn from each vessel using a syringe after 10, 20, 30, 40, 50 and 60 minutes and an equivalent amount of the dissolution medium was immediately introduced as a replacement. The samples were filtered and suitably diluted with the dissolution medium. The concentrations were determined by measuring the absorbance at 276 nm using a UV/VIS spectrophotometer, Spectro genesis 5 (UK). Solution of ciprofloxacin reference standard was also prepared using the dissolution medium and absorbance was measured. Water was used as a blank. All the necessary corrections for dilution were made when calculating the percent of drug released and calibration curve for the dissolution was set.
Assay of ciprofloxacin tablets
All the eight drug products were assayed for the drug content according to the method outlined in ml of water. The solution was sonicated for 20 minutes and filtered. A portion of the filtrate (25 ml) was withdrawn and diluted with sufficient amount of the mobile phase to give 100 ml solution. 58 mg of the reference standard was dissolved in 100 ml of the mobile phase. The solutions were made ready on the sample vials and 10 µl of each were injected to the system at intervals. The assays were repeated three times and the results presented were the mean of the three determinations. The content of ciprofloxacin was calculated from the peak areas of the chromatograms of the test and reference standard solutions and the declared content of ciprofloxacin in ciprofloxacin hydrochloride reference standard.
Data Analysis
Analytical data obtained from the experiments carried out were analyzed using ORIGIN ® graphing and scientific analysis software program for manipulating and drawing of dissolution profiles; and GrahPad InStat Demo software program for statistical comparisons of dissolution profiles.
RESULTS AND DISCUSSION
Identification test of ciprofloxacin tablets
The thin layer chromatographic (TLC) results for the identification of the drug samples are shown in table 2. The retention factor (R f ) of both the sample and the reference substance was calculated and compared. The TLC plates were examined under UV-light of 254 nm. The results from table 2 revealed that the R f values of the samples and the reference standard were almost the same. Thus, all the samples examined for the identity of the active ingredient passed the identification test as per the BP and USP/NF specifications. 
Weight uniformity test
The results of weight uniformity test are depicted in table 3. The mean tablet weight, the number of tablets within and outside the BP specification limit range for the different products is included.
Weight uniformity test is required to assure that the drug content in each unit dose is distributed in a narrow range around the label strength. If the drug substance forms the greater part of the oral solid dosage form, any weight variation obviously reflects variation in the content of active ingredient. According to the specification outlined in BP 2004, the test for uniformity of weight for drug products where the strength is >250 mg (film coated tablets), a ±5% of the average pass the test for uniformity of weight. The results, thus, indicate that six of the products possess acceptable uniformity of weight as per the pharmacopoeia limit. Moreover, the relative standard deviation of the products is less than 6 and the number of tablets outside the BP range is within the limit stipulated in the pharmacopoeia. 
Disintegration test
The mean disintegration times of the different brands of the ciprofloxacin tablets included in the study is shown in table 4. As indicated in the table, the mean disintegration time for all the products was within the pharmacopoeia limit. For a drug to be absorbed from a solid dosage form after oral administration, it must first be in solution, and the first important step toward this condition is usually the break-up of the tablet; a process known as disintegration. According to the BP 2004, the time limit for disintegration of film coated tablets is <30 min. All the products comply with the outlined specification time for disintegration of film coated tablets. Moreover all the drug products had a mean disintegration time of less than five minutes. 
Assay of ciprofloxacin tablets
The results for the mean percentage label claim of the different brands of ciprofloxacin 500 mg tablets included in the study are depicted in 
Dissolution test
The dissolution profile of the six brands is illustrated in figure 1 (FDA, 1997; Sathe et al., 1997 Sathe et al., , 2001 ). 
CONCLUSION
The study attempted to assess the quality of ciprofloxacin tablets and the physicochemical equivalence of the six brands. The physicochemical evaluation showed that all of the ciprofloxacin tablets tested for identity of the active ingredient, weight uniformity, and disintegration time complied with the pharmacopoeial specifications described in the BP and USP/NF. Moreover, the ciprofloxacin tablets included in the study have mean drug content within the compendial tolerance limits. Statistical comparison for drug content indicates that with 95% confidence interval, there is no significant difference among the brands (P<0.05). Five brands complied with the BP and USP dissolution tolerance limits but Ciflox failed to release the stated amount. In addition, the six brands showed that there is significant difference in the drug release in vitro (p<0.05). To justify the specification limits of the in vitro dissolution test, further study should be made to establish a meaningful correlation between in vitro release characteristics and in vivo bioavailability parameters. Hence, the safety, quality and efficacy of essential drugs in the region, should be continuously monitored through post marketing surveillance practices.
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